MTOR and neoplasm: Inhibited PI3K-Akt-mTOR signaling: Reduced downstream HIF-1α/VEGFA expression, breaking the hypoxia-angiogenesis-immunosuppression cycle.<h4>Conclusion</h4>HYW enhances ICIs efficacy in TNBC by normalizing tumor vasculature and remodeling the tumor immune microenvironment (TIME), which provides a novel rationale for combining TCM with ICIs to improve TNBC treatment outcomes.